A new tool co-developed by investigators from Cedars-Sinai Health Sciences University can predict which of two available chemotherapy options for pancreatic cancer would be more effective for an ...
Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual ...
After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic ...
Long before his personal battle with blood cancer, Neyens began participating on the Everett Fire Department team in the Firefighter Stairclimb, an annual event that has raised nearly $30 million ...
Cedars Sinai tool predicts the best chemotherapy regimen for advanced pancreatic cancer using AI analysis of biopsy images.
Abstracts presented at ASCO GU examined whether the radioligand therapy impacts or is affected by ARPIs or chemotherapy.
23h
Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1
As announced, Jaguar received an up-front payment of $16M of non-dilutive capital in January 2026 upon entering U.S.
February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and survivorship lung health.
A Lafayette father's battle with stage 4 pancreatic cancer is taking a hopeful turn as he becomes the first in Colorado to receive a newly approved targeted therapy.
For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials
Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after one ARPI and delayed chemotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results